{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:50:15Z","timestamp":1777596615428,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1038\/sj.bjc.6605604","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T21:05:06Z","timestamp":1268773506000},"page":"1099-1105","source":"Crossref","is-referenced-by-count":168,"title":["The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer"],"prefix":"10.1038","volume":"102","author":[{"name":"on behalf of the AZURE (BIG01\/04) Investigators","sequence":"first","affiliation":[]},{"given":"R E","family":"Coleman","sequence":"first","affiliation":[]},{"given":"M C","family":"Winter","sequence":"additional","affiliation":[]},{"given":"D","family":"Cameron","sequence":"additional","affiliation":[]},{"given":"R","family":"Bell","sequence":"additional","affiliation":[]},{"given":"D","family":"Dodwell","sequence":"additional","affiliation":[]},{"given":"M M","family":"Keane","sequence":"additional","affiliation":[]},{"given":"M","family":"Gil","sequence":"additional","affiliation":[]},{"given":"D","family":"Ritchie","sequence":"additional","affiliation":[]},{"given":"J L","family":"Passos-Coelho","sequence":"additional","affiliation":[]},{"given":"D","family":"Wheatley","sequence":"additional","affiliation":[]},{"given":"R","family":"Burkinshaw","sequence":"additional","affiliation":[]},{"given":"S J","family":"Marshall","sequence":"additional","affiliation":[]},{"given":"H","family":"Thorpe","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,3,16]]},"reference":[{"key":"BF6605604_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE, Geyer Jr CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019\u20132027","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR2","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1002\/cncr.23083","volume":"110","author":"AU Buzdar","year":"2007","unstructured":"Buzdar AU (2007) Preoperative chemotherapy treatment of breast cancer \u2013 a review. Cancer 110: 2394\u20132407","journal-title":"Cancer"},{"key":"BF6605604_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/jnci\/dji206","volume":"97","author":"LA Carey","year":"2005","unstructured":"Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97: 1137\u20131142","journal-title":"J Natl Cancer Inst"},{"key":"BF6605604_CR4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1200\/JCO.2004.09.062","volume":"22","author":"AM Chen","year":"2004","unstructured":"Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22: 2303\u20132312","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"BF6605604_CR5","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.3816\/CBC.2007.s.004","volume":"7","author":"R Coleman","year":"2007","unstructured":"Coleman R (2007) Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 7 (Suppl 1): S29\u2013S35","journal-title":"Clin Breast Cancer"},{"key":"BF6605604_CR6","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483\u20132493","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672\u20132685","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 360: 679\u2013691","journal-title":"New Engl J Med"},{"key":"BF6605604_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/JCO.2007.15.3510","volume":"26","author":"JR Gralow","year":"2008","unstructured":"Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26: 814\u2013819","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"American Joint Committee on Cancer Staging Manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow MH (2002) American Joint Committee on Cancer Staging Manual, 6th edn. Springer-Verlag: New York"},{"issue":"Suppl 2","key":"BF6605604_CR11","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.3816\/CBC.2002.s.015","volume":"3","author":"SD Heys","year":"2002","unstructured":"Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O (2002) Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3 (Suppl 2): S69\u2013S74","journal-title":"Clin Breast Cancer"},{"key":"BF6605604_CR12","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1158\/0008-5472.CAN-07-6520","volume":"68","author":"JS Jeruss","year":"2008","unstructured":"Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK (2008) Staging of breast cancer in the neoadjuvant setting. Cancer Res 68: 6477\u20136481","journal-title":"Cancer Res"},{"key":"BF6605604_CR13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","volume":"18","author":"M Kaufmann","year":"2007","unstructured":"Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18: 1927\u20131934","journal-title":"Ann Oncol"},{"key":"BF6605604_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460\u2013469","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"BF6605604_CR15","doi-asserted-by":"publisher","first-page":"S387","DOI":"10.1016\/S0753-3322(05)80085-X","volume":"59","author":"K Kuroi","year":"2005","unstructured":"Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F (2005) Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother 59 (Suppl 2): S387\u2013S392","journal-title":"Biomed Pharmacother"},{"key":"BF6605604_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2325\/jbcs.13.254","volume":"13","author":"M Kurosumi","year":"2006","unstructured":"Kurosumi M (2006) Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer (Tokyo, Japan) 13: 254\u2013259","journal-title":"Breast Cancer (Tokyo, Japan)"},{"key":"BF6605604_CR17","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/bjc.1996.565","volume":"74","author":"G MacGrogan","year":"1996","unstructured":"MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458\u20131465","journal-title":"Br J Cancer"},{"key":"BF6605604_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/bjs.5894","volume":"94","author":"JS Mieog","year":"2007","unstructured":"Mieog JS, van der Hage JA, van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94: 1189\u20131200","journal-title":"Br J Surg"},{"key":"BF6605604_CR19","unstructured":"NHS Breast Cancer Screening Programme (NHSBSP) and The Royal College of Pathologists (2005) NHSBSP Guidelines for Pathology Reporting in Breast Disease Publication No. 58: 1\u2013134"},{"issue":"2","key":"BF6605604_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ijc.24756","volume":"126","author":"PD Ottewell","year":"2010","unstructured":"Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 126 (2): 522\u2013532","journal-title":"Int J Cancer"},{"key":"BF6605604_CR21","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jnci\/djn240","volume":"100","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167\u20131178","journal-title":"J Natl Cancer Inst"},{"key":"BF6605604_CR22","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","volume":"20","author":"R Rouzier","year":"2002","unstructured":"Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304\u20131310","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ncponc0520","volume":"3","author":"D Santini","year":"2006","unstructured":"Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G (2006) Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 3: 325\u2013338","journal-title":"Nat Clin Pract Oncol"},{"key":"BF6605604_CR24","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25: 4414\u20134422","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR25","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","volume":"19","author":"JA van der Hage","year":"2001","unstructured":"van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224\u20134237","journal-title":"J Clin Oncol"},{"key":"BF6605604_CR26","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/bcr1989","volume":"10","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10: R30","journal-title":"Breast Cancer Res"},{"key":"BF6605604_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34","author":"MC Winter","year":"2008","unstructured":"Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453\u2013475","journal-title":"Cancer Treat Rev"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605604","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:44:35Z","timestamp":1684413875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["BF6605604"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605604","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}